本帖最后由 老马 于 2013-3-13 13:43 编辑 $ x2 V3 i2 \* a \0 z; |) ^# m
# U( f2 @; a; M3 {2 X4 J1 W
健择（吉西他滨）+顺铂+阿瓦斯汀( z! N: Y) X {' l; m
Gemzar +Cisplatin + Avastin- U* O7 q! j8 _# Q& h0 N- N# J
http://annonc.oxfordjournals.org/content/21/9/1804.full/ m) x( q1 b+ E/ H/ h# d7 ^: R
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 t9 R# { u" W# `7 [
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ' N( I0 w) l- }: T" {6 z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 }6 c1 f: Z t* p" ]! g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 228)
+ C! ` D' l1 W9 m) h/ l
华为网盘附件：+ P1 a7 F( j, x2 C+ `, e/ r
【华为网盘】ava.JPG
. I5 W7 _% g: i6 m3 u" R |
显身卡
